Northern Cancer Alliance - MDT --
Chairs and Leaders Development Programme 2018

Background

Cancer MDTs have existed since 1996. Cancer Research UK (CRUK) produced a review paper outlining recommendations to improve the effectiveness of MDTs in response to increasing caseloads, changes and advances in diagnostics and treatments and the increase in complex cases. The Northern Cancer Alliance identified that investment in their 80+ chairs of MDTs would be a critical step in achieving the full recommendations.  Northern Cancer Alliance, through a competitive process, commissioned Prospect to design, deliver and evaluate a programme across Spring and Summer 2018.

Prospect have a significant track record in working with medics, clinicians and managers across multiple organisations to build engagement and agreement to collaborate – be that for leadership development, service re-design or restructures.

 

Activity               

 

Prospect’s business manager and allocated administration lead managed all pre-programme activity, such as preparing a publicity flyer, issuing pre-programme surveys, and distributed self-assessment and psychometrics for the Thomas Kilmann Conflict Style Tool, and Negotiation Style Tool.

 

For diagnostics, Prospect interviewed 6 MDT chairs, designed, tested and issued a bespoke survey based on the CRUK recommendations (which received a 33% response in very short timescale), analysed findings and produced a report for sterring group with recommendations, and discussed findings with the steering group, triangulating this with CRUK recommendations and agreed priorities for the programme.

Prospect hosted 2 half-day pilot workshops, to design to masterclass programmes. Masterclass One was aimed at leading and chairing the MDT, which was hosted four times. Masterclass two was aimed at dealing with challenging issues, and was hosted six times. Each masterclass was facilitated by two facilitators, for the second masterclass, two actors supported handling conflict exercises.

 

A bespoke evaluation was produced for each workshop, measuring the delegates’ learning experiences, effectiveness of facilitation and delivery of learning objectives, using a five scale Likert scale.  Delegates could also leave free text feedback. The Cancer Alliance sought informal follow up and feedback in Alliance meetings and through the Trust cancer leads.

 

Prospect gathered discussion outputs (with permission from delegates) from system mapping exercises, and summarised these in a report for the Cancer Alliance as these highlighted some common issues and ideas for further improvement.

 

 

Results

There are approximately 80 Cancer MDT Chairs and Leads – the target number for participation was 60.  73 people participated in the programme – 61 attended Masterclass 1 and 58 Masterclass 2.  This is a participation rate of 91.25%, with most attending both workshops.

 

For all workshops and across all measures, more than 96% agreed or strongly agreed that the programme met the specific learning objectives and was facilitated effectively.